Processing

Please wait...

Settings

Settings

Goto Application

1. IN202017018874 - COMPOSITION FOR CYTOTOXIC T CELL DEPLETION

Office
India
Application Number 202017018874
Application Date 04.05.2020
Publication Number 202017018874
Publication Date 07.08.2020
Publication Kind A
IPC
A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 29/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
A61P 37/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
06Immunosuppressants, e.g. drugs for graft rejection
A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Applicants DAIICHI SANKYO COMPANY, LIMITED
Inventors MUKASA Ryuta
KIYOSAWA Naoki
YAMADA Shinnosuke
Priority Data 2017-194945 05.10.2017 JP
Title
(EN) COMPOSITION FOR CYTOTOXIC T CELL DEPLETION
Abstract
(EN) Provided is a novel composition. A composition for cytotoxic T cell depletion, the composition including an anti-LAG-3 antibody or a binding fragment thereof that has the properties described in (i) to (iii): (i) has in vitro ADCC activity; (ii) reduces the number of LAG-3-positive cells in vivo in low-fucose form; and (iii) binds to human activated T cells.